Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05399641 · ClinicalTrials.gov registry record · Phase 3
Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis
A Phase 3 study, sponsored by Scynexis.
- Completed
- Registry status
- Phase 3
- Development phase
- 150
- Enrollment target
NCT05399641 is a Phase 3 study that has completed, run by Scynexis. The registered enrollment target is 150 participants.
The verdict
NCT05399641, a Phase 3 study, has completed, sponsored by Scynexis.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 150 participants
- Enrollment target
Study Summary
This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.
Interventions
- DRUG Ibrexafungerp
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 150 participants |
| Start Date | 2022-05-01 |
| Est. Completion | 2023-08-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05399641
The ClinicalTrials.gov registry entry for NCT05399641 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Scynexis, which has 13 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Ibrexafungerp is the first listed.
NCT05399641 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05399641 about?
NCT05399641 is a clinical study titled "Ibrexafungerp for the Treatment of Complicated Vulvovaginal Candidiasis". This study will treat subjects with complicated VVC who have failed prior fluconazole therapy with Ibrexafungerp for 1, 3 or 7 days of treatment.
What is the current status of trial NCT05399641?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2022-05-01. Estimated completion is 2023-08-02.
What interventions are being tested in trial NCT05399641?
The interventions under investigation include: Ibrexafungerp (DRUG).
Who is sponsoring clinical trial NCT05399641?
This trial is sponsored by Scynexis, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.